We calibrated our model to experimentally derived cytokine cocktails, identified the baseline immune response to CDI using our model, simulated treatment of CDI with ABA or IL-2 in a comparison study, and identified gluconeogenesis via PEPCK-M as an emerging metabolic pathway implicated in the induction Treg responses. The gene discussed is PCK2; the disease is clostridium difficile infection.